
Grant Funds Development of a Novel Malaria Vaccine
iQur and the Edward Jenner Institute for Vaccine Research announced that that they will receive a grant of 152,000 EUR ($201,523) from the Technology Strategy Board's Biocatalyst fund to develop a novel malaria vaccine.
A proof of concept study will be carried out in which iQur will make VLPs carrying specific malaria targets that have been identified by the Jenner. If the project is successful, further funding will be sought to progress the targets into a clinical trial.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.